scholarly journals Thyroxine absorption test protocol for hypothyroid patients on high dose thyroxine replacement

The Physician ◽  
2020 ◽  
Vol 6 (3) ◽  
Author(s):  
Aldons Carlo Chua ◽  
S Ahmed ◽  
U Dashora ◽  
P Sathiskumar ◽  
M Ravelo ◽  
...  

Abstract presented at the Phillippine Nurses UK World Cafe Convention, 24 October 2020

2013 ◽  
pp. 65-71 ◽  
Author(s):  
Mitsuru Ito ◽  
Akira Kitanaka ◽  
Takeshi Arishima ◽  
Takumi Kudo ◽  
Eijun Nishihara ◽  
...  

2017 ◽  
Vol 7 (3) ◽  
pp. 187-193
Author(s):  
Ahmed Salam Mir ◽  
Zafar Ahmed Latif ◽  
SM Ashrafuzzaman ◽  
Faria Afsana

Background: Hypothyroidism is an important endocrine disorder associated with deleterious effects on multiple systems including cardiovascular, musculoskeletal, renal and nervous system. It is established that thyroxine replacement shows improvement in many clinical and biochemical parameters of overt hypothyroidism, but there is scarce data about these disorders in this sub-continent. The present study intends to find out the effect of thyroxine replacement on lipid profile and renal function in hypothyroid patients.Methods: This was an observational cohort study, done in endocrine inpatient and outpatient departments of BIRDEM General Hospital from August 2013 to July 2014. Patients with newly detected hypothyroidism, both primary and subclinical, were selected by convenient sampling. A semi-structured questionnaire was used to collect the clinical and laboratory informations from the patients. Baseline clinical and laboratory informations including lipid profile and serum creatinine were collected and e-GFR was calculated. Then tablet levothyroxine was started at a dose of 25 micrograms/day and adjusted by 12.5-25 micrograms/day dose increments 4-6 weekly till FT4 and TSH were normalized. After 6 months, clinical and biochemical data were collected and e-GFR calculated.Results: Seventy four hypothyroid patients were followed up for 6 months. All the patients became euthyroid during this time with thyroxine replacement (mean daily dose of thyroxine 96.61 ±25.62 micrograms). There was significant improvement in hypothyroid symptoms and significant reduction in weight and systolic and diastolic blood pressure in the patients after thyroxine replacement. There was reduction in total cholesterol (187.66 ±19.90 mg/dl to 164.37±17.49 mg/dl, P<0.001), LDL (P<0.001) and triglycerides (P<0.001) but HDL did not increase significantly (31.93 ±2.99 mg/dl to 31.98 ±2.75 mg/dl, P=0.46). Renal function improved significantly in terms of eGFR (74.78±13.70 ml/min/1.73m2 to 89.23±18.24 ml/min/1.73m2, P<0.001).Conclusion: The present study concludes that there is increased prevalence of dyslipidaemia and renal dysfunction in hypothyroid patients in this cross-sectional population. Adequate replacement of thyroxine can, at least in part, reverse these problems. It also shows significant improvement of the patients with subclinical hypothyroidism, which is regarded by many authors as mild thyroid failure.Birdem Med J 2017; 7(3): 187-193


2010 ◽  
Vol 54 (5) ◽  
pp. 435-442 ◽  
Author(s):  
Laura S. Ward

Although most hypothyroid patients do well with one single tablet of thyroxine daily, approximately 10% are dissatisfied and another important group of patients is difficult to control. We reviewed the most common causes for frequent-dose adjustment or high-dose requirement, including poor compliance with therapy and inadequate medication. Since these two causes have been ruled out, drug interaction and other concomitant diseases need to be investigated. Requirements of thyroxine increase in all conditions characterized by impaired gastric acid secretion. Proton-pump inhibitors, antacids and a long list of drugs may decrease thyroxine absorption. In addition, a series of diseases including celiac disease and chronic inflammatory intestinal diseases, as well as nutritional habits may be important in patient control. Finally, we mention the effects of a growing list of drugs and thyroid disruptors that may also affect thyroid hormone metabolism at many levels.


1987 ◽  
Vol 116 (3) ◽  
pp. 418-424 ◽  
Author(s):  
K. Liewendahl ◽  
T. Helenius ◽  
B.-A. Lamberg ◽  
H. Mähönen ◽  
G. Wägar

Abstract. Free thyroxine (FT4) and free triiodothyronine (FT3) concentrations in serum were measured by direct equilibrium dialysis methods in patients receiving thyroxine replacement or suppression therapy. Four of 50 hypothyroid patients euthyroid on replacement therapy (mean thyroxine dose 120 μg/day) had supra-normal FT4 concentrations, whereas the FT3 concentrations were normal in all. Forty-one of 56 operated thyroid carcinoma patients on suppressive therapy (mean thyroxine dose 214 μg/day) had raised FT4 concentrations, whereas the FT3 concentration was elevated in only one patient. There was a large difference in mean FT4 values for hypothyroid and thyroid carcinoma patients (17.2 vs 29.5 pmol/l), whereas the difference in mean FT3 values was small (5.0 vs 6.1 pmol/l), suggesting a decreased peripheral conversion of T4 to T3 with increasing concentrations of FT4. Serum TSH concentrations, as determined by an immunoradiometric assay, varied from < 0.02 to 11.9 mU/l in treated hypothyroid patients; 21 patients (42%) had values outside the reference limits. As a single test, serum TSH is therefore not very useful for the assessment of adequate thyroxine dosage in patients with primary hypothyroidism. In thyroid carcinoma patients, the TSH concentrations were < 0.18 mU/l; 45 patients had values < 0.02 mU/l indicating sufficient suppression of TSH secretion in the majority of cases. On the basis of these results we recommend the combination of FT3 and TSH tests for monitoring thyroxine replacement and suppression therapy. FT4 appears less useful than FT3 for this purpose even if special reference values values were adopted for each patient group.


1989 ◽  
Vol 121 (5) ◽  
pp. 674-676 ◽  
Author(s):  
Ian Sturgess ◽  
Simon H. Thomas ◽  
Dudley J. Pennell ◽  
Derek Mitchell ◽  
Desmond N. Croft

Abstract. Eleven patients with treated hypothyroidism were investigated to examine the effects of time on their thyroid function tests. Each patient was clinically and biochemically euthyroid on once daily thyroxine replacement therapy, taken in the morning. TSH followed a diurnal rhythm with a peak level at 23.30 h and a trough level at 14.30 h. Four subjects had TSH trough levels within the normal range, but with peak levels outside this range. FT4 and FT3 levels fell from their highest levels some three hours after ingestion to the lowest levels just prior to the next dose. This study shows that there are significant time-related variabilities in TSH and thyroid hormone levels in treated hypothyroid patients. This should be taken into account when interpreting results of their thyroid function tests.


Sign in / Sign up

Export Citation Format

Share Document